Dojolvi

News

Ultragenyx gets first Euro nod for rare disease drug Dojolvi

Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.

News

FDA backs second rare disease drug from Ultragenyx in the sp...

The FDA has approved a second rare disease drug from California-based Ultragenyx in the space of a fortnight, for treatment of long-chain fatty acid oxidation disorders.&nbs

News

Cure HHT wins inaugural Prix Galien Patient First Award

A patient-led initiative for hereditary haemorrhagic telangiectasia (HHT) has won the inaugural Prix Galien Patient First Award.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks